US Eases Access to Marijuana for Medical Use, Reclassifying Drug to Schedule III
Washington D.C. - In a significant shift in federal drug policy, the United States government has made it easier for Americans to access marijuana for medical reasons by reclassifying the drug. Effective immediately, FDA-approved marijuana products and marijuana products regulated by state medical license programs have been moved from the most restrictive Schedule I to Schedule III of the Controlled Substances Act. This move, signed by Acting Attorney General Todd Blanche on April 23, 2026, acknowledges the recognized medical value of cannabis and allows for expanded patient access and increased research into its safety and efficacy [1, 3, 8].
Previously, marijuana was categorized under Schedule I, alongside drugs like heroin and methamphetamine, indicating no accepted medical use and a high potential for abuse [2, 5]. The reclassification to Schedule III, which includes substances like ketamine and anabolic steroids, signifies a moderate to low potential for addiction and abuse, aligning with the reality of its increasing use and acceptance at the state level [2, 4, 9]. This change is a direct follow-up to President Donald Trump's executive order in December 2025, aimed at increasing research into medical marijuana [1, 3].
The reclassification does not legalize marijuana for recreational use at the federal level, nor does it change the status of marijuana not distributed through state-licensed medical programs, which will remain under Schedule I [4, 7]. However, the move is expected to remove barriers for medical research, allowing scientists to study cannabis-derived substances more readily [9, 10]. Furthermore, state-licensed medical marijuana producers and distributors will now have an expedited process to register with the U.S. Drug Enforcement Administration, and for the first time, they will be able to deduct business expenses on their federal taxes, a significant financial benefit for the industry [7, 9].
While welcomed by advocates as a historic step towards a more rational cannabis policy, some believe this move doesn't go far enough. They argue that marijuana should be descheduled entirely to address issues such as ongoing possession arrests and the disconnect between federal prohibition and state-regulated markets [4]. A new administrative hearing is scheduled to begin on June 29, 2026, to consider the broader rescheduling of marijuana, potentially leading to further changes in its federal status [3, 6, 10]. The Department of Justice has stated that these actions provide immediate clarity for researchers, patients, and providers while maintaining strict federal controls against illicit drug trafficking [10].
Previously, marijuana was categorized under Schedule I, alongside drugs like heroin and methamphetamine, indicating no accepted medical use and a high potential for abuse [2, 5]. The reclassification to Schedule III, which includes substances like ketamine and anabolic steroids, signifies a moderate to low potential for addiction and abuse, aligning with the reality of its increasing use and acceptance at the state level [2, 4, 9]. This change is a direct follow-up to President Donald Trump's executive order in December 2025, aimed at increasing research into medical marijuana [1, 3].
The reclassification does not legalize marijuana for recreational use at the federal level, nor does it change the status of marijuana not distributed through state-licensed medical programs, which will remain under Schedule I [4, 7]. However, the move is expected to remove barriers for medical research, allowing scientists to study cannabis-derived substances more readily [9, 10]. Furthermore, state-licensed medical marijuana producers and distributors will now have an expedited process to register with the U.S. Drug Enforcement Administration, and for the first time, they will be able to deduct business expenses on their federal taxes, a significant financial benefit for the industry [7, 9].
While welcomed by advocates as a historic step towards a more rational cannabis policy, some believe this move doesn't go far enough. They argue that marijuana should be descheduled entirely to address issues such as ongoing possession arrests and the disconnect between federal prohibition and state-regulated markets [4]. A new administrative hearing is scheduled to begin on June 29, 2026, to consider the broader rescheduling of marijuana, potentially leading to further changes in its federal status [3, 6, 10]. The Department of Justice has stated that these actions provide immediate clarity for researchers, patients, and providers while maintaining strict federal controls against illicit drug trafficking [10].
This article and image are AI generated. For informational purposes only.